TITLE

AVELOX, FAST-ACTING ANTIBIOTIC, APPROVED IN CANADA

PUB. DATE
December 2000
SOURCE
Worldwide Biotech;Dec2000, Vol. 12 Issue 12, p8
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports the Health Canada's approval of Avelox, an antibiotic designed by Bayer Inc. to rapidly treat patients suffering from common respiratory tract infections. Reports on the approval by Health Canada of the antibiotic Avelox(R), developed by Bayer Inc. Statement that Avelox was designed to rapidly treat patients suffering from common respiratory tract infections; Benefits of Avelox over other antibiotics; Comments of Philip Blake, Executive Vice President and General Manager, Healthcare Division, Bayer Inc.
ACCESSION #
3905754

 

Related Articles

  • Bush Administration Talks to Bayer About Relaxing Its Antibiotic Cipro Patent.  // Chemical Market Reporter;10/22/2001, Vol. 260 Issue 15, p4 

    Reports that the United States government requested Bayer AG to relax its patent on the antibiotic Cipro, or ciprofloxacin, an oral treatment of anthrax. Response of Bayer to anthrax cases in the country; Measures undertaken by the government to boost emergency drug stockpiles; Average...

  • Stuart Elliott in America. Elliott, Stuart // Campaign;11/2/2001, Issue 44, p27 

    Comments on pharmaceutical firm Bayer AG's decision to lower the price of its anthrax antibiotic, Cipro, in the United States. Response to threat by U.S. Congress to break firm's patent to Cipro; Resentment among American consumers over high prices for prescription drugs.

  • Bayer to Triple Production of Anthrax Drug. Westervelt, Robert // Chemical Week;10/24/2001, Vol. 163 Issue 39, p13 

    Reports that Bayer AG will triple United States production of Cipro, the only antibiotic approved for the treatment of pulmonary anthrax, in response to more reports of anthrax exposure in the United States. Why senators called for Bayer to ease or abandon its United States patent protection;...

  • ANTHRAX FEARS COME HOME.  // Business News New Jersey;10/23/2001, Vol. 14 Issue 43, p3 

    Reports on the widespread fears of anthrax in New Jersey. Letters containing anthrax spores sent to Senate Majority Leader Tom Daschle and NBC News anchor Tom Brokaw; Detection of household powder sprinkled on ATM-machine keyboards as a prank; Development of Cipro antibiotic by Bayer AG as...

  • New database could lead to antibiotic overuse. Dove, Alan // Nature Medicine;Dec2000, Vol. 6 Issue 12, p1304 

    Reports that a database sponsored by Bayer AG will use information on the incidence of respiratory tract infections (RTI) to help market antibiotics directly to consumers. Information that the RTIalert database will provide; System of data collection designed by Surveillance Data Inc. for the...

  • Pharmaceutical Patents and Public Safety. Calfee, John E. // Consumers' Research Magazine;Nov2001, Vol. 84 Issue 11, p14 

    Discusses the plan of the United States government to abridge the patent of ciproflaxin or Cipro from Bayer company to provide less expensive antibiotics against anthrax. Rise in demand for Cipro after cases of anthrax; Suggestions to fight bioterrorism threats; Impact of the Cipro patent...

  • Bayer cuts price of ciprofloxacin after Bush threatens to buy generics. Charatan, Fred // BMJ: British Medical Journal (International Edition);11/3/2001, Vol. 323 Issue 7320, p1023 

    Reports that the German pharmaceutical company Bayer AG has agreed to lower its price for its antibiotic ciprofloxacin after the United States government threatened to buy generic alternatives to treat cases of anthrax. Recommendation of ciprofloxacin for the treatment of anthrax by the Centers...

  • FDA to Ban Two Animal Antibiotics. Franz, Neil // Chemical Week;11/8/2000, Vol. 162 Issue 42, p20 

    Discusses the proposal of the United States Food and Drug Administration (FDA) to ban two fluoroquinolone antibiotics used on turkeys and chickens. Concerns raised by the Centers for Disease Control and Prevention and other health agencies on the possible effects of the drugs to humans; Plan of...

  • Bayer to boost engineering resins.  // Chemical Week;9/13/1995, Vol. 157 Issue 9, p5 

    Reports that Bayer will invest $20 million at its Ohio plant to more than double production of engineering thermoplastics for computer housings, medical equipment and automotive applications. Product lines.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics